Latest From Geron Corp.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.
The company outlined pharma growth drivers, including 14 currently marketed medicines that will achieve $1bn or more in sales by 2020 and 10 new filings through 2023.
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.
Tris acquires Pfizer subsidiary Nextwave, which developed pair of ADHD drugs using Tris delivery technology. Lilly gets oral CGRP candidate from Chugai, while Dova signs US co-promotion partner for Doptelet.
- Antisense, Oligonucleotides
- Large Molecule
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Geron Corp.
- Senior Management
John A Scarlett, MD, Pres. & CEO
Olivia K Bloom, EVP, Fin. & CFO
Melissa A Behrs, EVP, Bus. Dev.
Andrew J Grethlein, PhD, EVP, Dev. & Technical Operations
Aleksandra Rizo, CMO
- Contact Info
Phone: (650) 473-7700
149 Commonwealth Dr.
Menlo Park, CA 94025